Monotherapy in R/R NKTCL achieved an ORR of 38%, a CR rate of 24% and response to avelumab was significantly associated with the expression of PD-L1 by tumor tissue (p = 0.001). The gene discussed is CD274; the disease is extranodal nasal NK/T cell lymphoma.